Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Yael L. Maxwell

October 24, 2025

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Michael O'Riordan

May 12, 2025

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

Todd Neale

December 12, 2023

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

Todd Neale

November 06, 2022

News Daily News

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Michael O'Riordan

April 10, 2019

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

News Daily News

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Michael O'Riordan

July 06, 2017

News Daily News

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

Michael O'Riordan

June 28, 2016

News Daily News

胆固醇治疗试验协作再次审视他汀类药物与不良事件之间的关系

Michael O'Riordan

June 13, 2016

News Daily News

La Colaboración de Ensayistas para el Tratamiento del Colesterol Vuelve a Analizar los Episodios Adversos secundarios a las Estatinas

Michael O'Riordan

June 13, 2016

News Daily News

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

Michael O'Riordan

June 13, 2016

Video

» On Record

On Record: The Obesity Crisis

September 18, 2024

Video

» Interview

Beyond the Data: Polypills, Screening, and Lifetime CVD Risk

September 6, 2022

Advertisement

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Statins and Diabetes: Causal Link Reinforced in New Analysis

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

胆固醇治疗试验协作再次审视他汀类药物与不良事件之间的关系

La Colaboración de Ensayistas para el Tratamiento del Colesterol Vuelve a Analizar los Episodios Adversos secundarios a las Estatinas

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

On Record: The Obesity Crisis

Beyond the Data: Polypills, Screening, and Lifetime CVD Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content